TGTX · Tg Therapeutics, Inc. · Share Buybacks

$53.56 -0.34 (-0.62%)

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$8.25B

153.07M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Program Authorized

$400,000,000

as of 2026-06-30 · total across 2 concurrent programs

Program Announced	Authorized	Remaining	As of	Runs Through	Source
2026-05-06	$300,000,000	$200,000,000	2026-05-06	—	8-K , filed 2026-05-06
2025-11-03	$100,000,000	—	—	—	8-K , filed 2026-02-26

Cash spent on buybacks by quarter

Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.

Repurchase History

Fiscal Year Ended	Cash Spent	Shares	Avg Price	Source
2015-12-31	$0	—	—	10-K, filed 2016-03-15
2014-12-31	$0	—	—	10-K, filed 2016-03-15
2013-12-31	$149,799	—	—	10-K, filed 2016-03-15
2012-12-31	$84,538	—	—	10-K, filed 2014-03-07

Quarter Ended	Cash Spent	Shares	Avg Price	Source
2014-03-31	$0	—	—	10-Q, filed 2014-05-14
2013-12-31	$149,799 Δ	—	—	10-K, filed 2016-03-15
2013-09-30	$0 Δ	—	—	10-Q, filed 2013-11-14
2013-06-30	$0 Δ	—	—	10-Q, filed 2013-08-09
2013-03-31	$0	—	—	10-Q, filed 2014-05-14
2012-12-31	$84,538 Δ	—	—	10-K, filed 2014-03-07
2012-09-30	$0 Δ	—	—	10-Q, filed 2013-11-14
2012-06-30	$0 Δ	—	—	10-Q, filed 2013-08-09
2012-03-31	$0	—	—	10-Q, filed 2013-05-14

Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 14 filings 13 filers Visit website Investor relations